Bench to bedside: Multiple actions of the PDE3 inhibitor cilostazol

Cyclic Nucleotide Phosphodiesterases in Health and Disease

Volumn , Issue , 2006, Pages 627-648

  Kambayashi, Junichi ^a   Shakur, Yasmin ^a   Liu, Yongge ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85132521865     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (122)

1. Poison, J.B., and S.J. Strada. 1996. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 36:403-127.
2. Hidaka, H., H. Hayashi, H. Kohri, et al. 1979. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J Pharmacol Exp Ther 211:26-30.
3. Lindgren, S.H., T.L. Andersson, E. Vinge, and K.E. Andersson. 1990. Effects of isozyme-selective phosphodiesterase inhibitors on rat aorta and human platelets: Smooth muscle tone, platelet aggregation and cAMP levels. Acta Physiol Scand 140:209-219.
4. Vigdahl, R.L., J. Mongin, Jr., and N.R. Marquis. 1971. Platelet aggregation. IV. Platelet phosphodiesterase and its inhibition by vasodilators. Biochem Biophys Res Commun 42:1088-1094.
5. Yamazaki, H., T. Motomiya, N. Mashimo, T. Asano, and H. Hidaka. 1978. Platelet aggregation and cyclic nucleotide phosphodiesterase activity in arteriosclerotic patients. Thromb Haemost 39:158-166.
6. Ikeda, Y., T. Sudo, and Y. Kimura. 2002. Cilostazol. In Platelets, ed A.D. Michelson, 817-823. Academic Press, San Diego, CA.
7. Hiatt, W.R. 2001. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344:1608-1621.
8. Liu, Y., Y. Shakur, M. Yoshitake, and J.J. Kambayashi. 2001. Cilostazol (Pletal): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 19:369-386.
9. Kambayashi, J., Y. Liu, B. Sun, Y. Shakur, M. Yoshitake, and F. Czerwiec. 2003. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 9:2289-2308.
10. Sun, B., S.N. Le, S. Lin, et al. 2002. New mechanism of action for cilostazol: Interplay between adenosine and cilostazol in inhibiting platelet activation. J Cardiovasc Pharmacol 40:577-585.
11. Wang, S., J. Cone, M. Fong, M. Yoshitake, J. Kambayashi, and Y. Liu. 2001. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 38:775-783.
12. Nishi, T., F. Tabusa, T. Tanaka, T. Shimizu, and K. Nakagawa. 1985. Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. IV. Synthesis and biological activity of the metabolites of 6-[4-(1-cyclohexyl-1H-5-tetrazolyl)butoxy]-2-oxo-1,2,3,4-tetrahydroquinoline (OPC-13013). Chem Pharm Bull (Tokyo) 33:1140-1147.
13. Shakur, Y., M. Fong, J. Hensley, et al. 2002. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovasc Drugs Ther 16:417-427.
14. Sudo, T., K. Tachibana, and K. Toga, et al. 2000. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 59:347-356.
15. Shakur, Y., L.S. Holst, T.R. Landstrom, M. Movsesian, E. Degerman, and V. Manganiello. 2001. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 66:241-277.
16. Liu, Y., M. Fong, J. Cone, S. Wang, M. Yoshitake, and J. Kambayashi. 2000. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 36:351-360.
17. Packer, M., J.R. Carver, R.J. Rodeheffer, et al. 1991. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325:1468-1475.
18. Packer, M. 1998. Treatment of chronic heart failure. Lancet 340:92-95.
19. Thadani, U., and D.M. Roden. 1998. FDA Panel report: January 1998. Circulation 97:2295-2296.
20. Dobson, J.G.J., and R.A. Fenton. 1998. Cardiac physiology of adenosine. In Cardiovascular biology of purines, eds. G. Burnstock, J.G.J. Dobson, B.T. Liang, and J. Linden, 21-39. Boston, MA: Kluwer Academic Publishers.
21. Narayan, P., R.M. Mentzer, Jr., and R.D. Lasley. 2000. Phosphatase inhibitor cantharidin blocks adenosine A(1) receptor anti-adrenergic effect in rat cardiac myocytes. Am J Physiol Heart Circ Physiol 278:H1-H7.
22. Cone, J., S. Wang, N. Tandon, et al. 1999. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 34:497-504.
23. Kimura, Y., T. Tani, T. Kanbe, and K. Watanabe. 1985. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35:1144-1149.
24. Uehara, S., and A. Hirayama. 1989. Effects of cilostazol on platelet function. Arzneimittelforschung 39:1531-1534.
25. Tani, T., K. Sakurai, Y. Kimura, T. Ishikawa, and H. Hidaka. 1992. Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells. Adv Second Messenger Phosphoprotein Res 25:215-227.
26. Kariyazono, H., K. Nakamura, T. Shinkawa, T. Yamaguchi, R. Sakata, and K. Yamada. 2001. Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol. Thromb Res 101:445-453.
27. Matsumoto, Y., K. Marukawa, H. Okumura, T. Adachi, T. Tani, and Y. Kimura. 1999. Comparative study of antiplatelet drugs in vitro: Distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses. Thromb Res 95:19-29.
28. Minami, N., Y. Suzuki, M. Yamamoto, et al. 1997. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci 61:L-9.
29. Tanigawa, T., M. Nishikawa, T. Kitai, et al. 2000. Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. Am J Cardiol 85:1054-1059.
30. Yasunaga, K., and K. Mase. 1985. Clinical effects of oral cilostazol on suppression of platelet function in patients with cerebrovascular disease. Arzneimittelforschung 35:1186-1188.
31. Woo, S.K., W.K. Kang, and K.I. Kwon. 2002. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans. Clin Pharmacol Ther 71:246-252.
32. Yasuda, K., M. Sakuma, and T. Tanabe. 1985. Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans. Arzneimittelforschung 35:1198-1200.
33. Saitoh, S., T. Saito, A. Otake, et al. 1993. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator. Arterioscler Thromb 13:563-570.
34. Kohda, N., T. Tani, S. Nakayama, et al. 1999. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res 96:261-268.
35. Li, H., J. Cone, M. Fong, J. Kambayashi, M. Yoshitake, and Y. Liu. 2005. Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation. Cardiovasc Drugs Ther 19:41-48.
36. Ikeda, Y., M. Kikuchi, H. Murakami, et al. 1987. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, doubleblind cross-over study. Arzneimittelforschung 37:563-566.
37. Tanemoto, K., Y. Kanaoka, and M. Kuinose. 2000. Assessment of antithrombotic agents using the platelet aggregation test. Cur Ther Res 61(11):798-806.
38. Ikeda, Y. 1999. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Thromb Haemost 82:435-438.
39. Igawa, T., T. Tani, T. Chijiwa, et al. 1990. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res 57:617-623.
40. Eisert, W.G. 2002. Dipyridamole. In Platelets, ed. A.D. Michelson, 803-815. New York: Academic Press.
41. Liu, Y., J. Cone, S.N. Le, et al. 2004. Cilostazol and dipyridamole synergistically inhibit human platelet aggregation. J Cardiovasc Pharmacol 44:266-273.
42. Nomura, S., N. Inami, T. Iwasaka, and Y. Liu. 2004. Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: Therapeutic effects by cilostazol and potentiation by dipyridamole. Platelets 15:167-172.
43. Kim, J.S., K.S. Lee, Y.I. Kim, Y. Tamai, R. Nakahata, and H. Takami. 2004. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: Analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 11:600-602.
44. Wilhite, D.B., A.J. Comerota, F.A. Schmieder, R.C. Throm, J.P. Gaughan, and R.A. Koneti. 2003. Managing PAD with multiple platelet inhibitors: The effect of combination therapy on bleeding time. J Vasc Surg 38:710-713.
45. Tamai, Y., H. Takami, R. Nakahata, F. Ono, and A. Munakata. 1999. Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis 29:269-276.
46. Mallikaarjun, S., W.P. Forbes, and S.L. Bramer. 1999. Interaction potential and tolerability of the coadministration of cilostazol and aspirin. Clin Pharmacokinet 37 (Suppl 2):87-93.
47. Nagakawa, Y., Y. Omaki, and H. Orimo. 1986. Effects of cilostazol (OPC-13013) on arachidonic acid metabolism. Jpn Pharmacol Ther 14:6319-6324.
48. Birk, S., C. Kruuse, K.A. Petersen, O. Jonassen, P. Tfelt-Hansen, and J. Olesen. 2004. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 24:1352-1358.
49. Wang, S., J. Cone, M. Fong, M. Yoshitake, J. Kambayashi, and Y. Liu. 2005. Cilostazol increases tissue blood flow and interstitial adenosine levels in stimulated rabbit gastrocnemius muscle [abstract]. J Mol Cell Cardio 38:868.
50. Takahashi, S., K. Oida, R. Fujiwara, et al. 1992. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 20:900-906.
51. Shimizu, E., Y. Kobayashi, Y. Oki, T. Kawasaki, T. Yoshimi, and H. Nakamura. 1999. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells. Life Sci 64:2081-2088.
52. Hayashi, S., R. Morishita, H. Matsushita, et al. 2000. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension 35:237-243.
53. Kim, M.J., K.G. Park, K.M. Lee, et al. 2005. Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension 45:552-556.
54. Rybalkin, S.D., and K.E. Bornfeldt. 1999. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation. Thromb Haemost 82:424-434.
55. Kayanoki, Y., W. Che, S. Kawata, Y. Matsuzawa, S. Higashiyama, and N. Taniguchi. 1997. The effect of cilostazol, a cyclic nucleotide phosphodiesterase III inhibitor, on heparin-binding EGF-like growth factor expression in macrophages and vascular smooth muscle cells. Biochem Biophys Res Commun 238:478-481.
56. Inoue, T., T. Uchida, M. Sakuma, et al. 2004. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol 44:1408-1414.
57. Morishita, R., J. Higaki, S.I. Hayashi, et al. 1997. Role of hepatocyte growth factor in endothelial regulation: Prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor. Diabetologia 40:1053-1061.
58. Lee, T.M., S.F. Su, C.H. Tsai, Y.T. Lee, and S.S. Wang. 2001. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Clin Sci (Lond) 101:305-311.
59. Nishio, Y., A. Kashiwagi, N. Takahara, H. Hidaka, and R. Kikkawa. 1997. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells. Horm Metab Res 29:491-495.
60. Omi, H., N. Okayama, M. Shimizu, et al. 2004. Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production. Microvasc Res 68:119-125.
61. Ishizaka, N., J. Taguchi, Y. Kimura, et al. 1999. Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis 142:41-46.
62. Kubota, Y., K. Kichikawa, H. Uchida, et al. 1995. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. Invest Radiol 30:532-537.
63. Aoki, M., R. Morishita, S. Hayashi, et al. 2001. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia 44:1034-1042.
64. Lee, J.H., G.T. Oh, S.Y. Park, et al. 2005. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 313:502-509.
65. Elam, M.B., J. Heckman, J.R. Crouse, et al. 1998. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 18:1942-1947.
66. Wang, T., M.B. Elam, W.P. Forbes, J. Zhong, and K. Nakajima. 2003. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. Atherosclerosis 171:337-342.
67. Tamai, T., A. Shimada, H. Maeda, et al. 1992. Reduction of low density lipoprotein by cilostazol in the non-insulin dependent diabetic patient. Jap Pharmacol Ther 20:241-248.
68. Watanabe, N., Y. Ishikawa, Y. Kitagawa, et al. 1996. Effects of cilostazol on the lipid metabolism in patients with hypertriglyceridemia. Jap Pharmacol Ther 24:127-132.
69. Ishikawa, M., Y. Yamada, C. Hirose, D. Tujino, K. Hoshi, and N. Saitou. 1997. The effects of cilostazol on serum lipid metabolism and ASO in NIDDM with hypertriglyceridemia. Ther Res 18:198-204.
70. Mishima, Y., A. Kuyama, M. Ando, M. Kibata, and T. Ishioka. 2000. Effects of cilostazol on serum lipoprotein concentrations and particle size of low-density lipoproteins in patients with dyslipidemic NIDDM. J Jap Atherosclerosis Soc 27:17-22.
71. Takayoshi, T., O. Shinichi, A. Ryuzo, et al. 2001. Effect of cilostazol on lipid, uric acid and glucose metabolism in patients with impaired glucose tolerance or type 2 diabetes mellitus: A double-blind, placebo-controlled study. Clinical Drug Investig 21:325-335.
72. Ikewaki, K., K. Mochizuki, M. Iwasaki, R. Nishide, S. Mochizuki, and N. Tada. 2002. Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus. Metabolism 51:1348-1354.
73. Nakamura, N., T. Hamazaki, H. Johkaji, et al. 2003. Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. Clin Exp Med 2:180-184.
74. Tani, T., K. Uehara, T. Sudo, K. Marukawa, Y. Yasuda, and Y. Kimura. 2000. Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Atherosclerosis 152:299-305.
75. Oscai, L.B., R.A. Caruso, and W.K. Palmer. 1986. Protein kinase activation of heparin-releasable lipoprotein lipase in rat heart. Biochem Biophys Res Commun 135:196-200.
76. Motoyashiki, T., M. Fukamachi, T. Morita, H. Shiomi, and H. Ueki. 1998. Involvement of adenosine in vanadate-stimulated release of lipoprotein lipase activity. Biol Pharm Bull 21:889-892.
77. Ranganathan, G., D. Phan, I.D. Pokrovskaya, J.E. McEwen, C. Li, and P.A. Kern. 2002. The translational regulation of lipoprotein lipase by epinephrine involves an RNA binding complex including the catalytic subunit of protein kinase A. J Biol Chem 277:43281-43287.
78. Londos, C., D.M. Cooper, W. Schlegel, and M. Rodbell. 1978. Adenosine analogs inhibit adipocyte adenylate cyclase by a GTP-dependent process: Basis for actions of adenosine and methylxanthines on cyclic AMP production and lipolysis. Proc Natl Acad Sci USA 75:5362-5366.
79. Larrouy, D., A. Remaury, D. Daviaud, and M. Lafontan. 1994. Coupling of inhibitory receptors with Gi-proteins in hamster adipocytes: Comparison between adenosine A1 receptor and alpha 2-adrenoceptor. Eur J Pharmacol 267:225-232.
80. Hadri, K.E., A. Courtalon, X. Gauthereau, A.M. Chambaut-Guerin, J. Pairault, and B. Feve. 1997. Differential regulation by tumor necrosis factor-alpha of beta1-, beta2-, and beta3-adrenoreceptor gene expression in 3T3-F442A adipocytes. JBiolChem 272:24514-24521.
81. Bullo, M., P. Garcia-Lorda, J. Peinado-Onsurbe, et al. 2002. TNFalpha expression of subcutaneous adipose tissue in obese and morbid obese females: Relationship to adipocyte LPL activity and leptin synthesis. Int J Obes Relat Metab Disord 26:652-658.
82. Greenberg, A.S., R.P. Nordan, J. McIntosh, J.C. Calvo, R.O. Scow, and D. Jablons. 1992. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: A possible role for interleukin 6 in cancer cachexia. Cancer Res 52:4113-4116.
83. Kim, K.Y., H.K. Shin, J.M. Choi, and K.W. Hong. 2002. Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 300: 709-715.
84. Maeda, E., G. Yoshino, K. Nagata, et al. 1993. Effect of cilostazol on triglyceride metabolism in rats. Curr Ther Res 54:420-424.
85. Lee, J.H., Y.K. Lee, M. Ishikawa, et al. 2003. Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats-an MRI study. Brain Res 994:91-98.
86. Lee, J.H., K.Y. Kim, Y.K. Lee, et al. 2004. Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats. J Pharmacol Exp Ther 308:896-903.
87. Choi, J.M., H.K. Shin, K.Y. Kim, J.H. Lee, and K.W. Hong. 2002. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 300:787-793.
88. Gotoh, F., H. Tohgi, S. Hirai, et al. 2000. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke and Carebrovasc Dis 9:147-157.
89. Otsuka America Pharmaceutical Inc. NDA 20-863: Cilostazol. 1997.
90. Ohashi, S., M. Iwatani, Y. Hyakuna, and Y. Morioka. 1985. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. Arzneimittelforschung 35:1203-1208.
91. Mishima, Y., S. Tanabe, T. Sakaguchi, T. Katsunma, A. Kusaba, and H. Uchida. 1986. Evaluation of OPC-13013 in chronic arterial occlusion. J Clin Exp Med 139:133-157 (in Japanese).
92. Dawson, D.L., B.S. Cutler, M.H. Meissner, and D.E.J. Strandness. 1998. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial. Circulation 98:678-686.
93. Money, S.R., J.A. Herd, J.L. Isaacsohn, et al. 1998. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 27: 267-274.
94. Beebe, H.G., D.L. Dawson, B.S. Cutler, et al. 1999. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med 159: 2041-2050.
95. Dawson, D.L., B.S. Cutler, W.R. Hiatt, et al. 2000. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 109:523-530.
96. CAPRIE Steering Committee. 1996. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348:1329-1339.
97. European Stroke Prevention Study. ESPS Group. 1990. Stroke 21:1122-1130.
98. Diener, H.C., L. Cunha, C. Forbes, J. Sivenius, P. Smets, and A. Lowenthal. 1996. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143:1-13.
99. Hwang, T.L., A. Saenz, J.J. Farrell, and W.L. Brannon. 1996. Brain SPECT with dipyridamole stress to evaluate cerebral blood flow reserve in carotid artery disease. J Nucl Med 37: 1595-1599.
100. Ito, H., T. Kinoshita, Y. Tamura, I. Yokoyama, and H. Iida. 1999. Effect of intravenous dipyridamole on cerebral blood flow in humans. A PET study. Stroke 30:1616-1620.
101. Ochiai, M., T. Isshiki, S. Takeshita, et al. 1997. Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen. Am J Cardiol 79:1471-1474.
102. Yoshitomi, Y., S. Kojima, T. Sugi, M. Yano, Y. Matsumoto, and M. Kuramochi. 1998. Anti-platelet treatment with cilostazol after stent implantation. Heart 80:393-396.
103. Park, S.W., C.W. Lee, H.S. Kim, et al. 1999. Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol 84:511-514.
104. Hashiguchi, M., K. Ohno, R. Nakazawa, S. Kishino, M. Mochizuki, and T. Shiga. 2004. Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. Cardiovasc Drugs Ther 18:211-217.
105. Schleinitz, M.D., I. Olkin, and P.A. Heidenreich. 2004. Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: A meta-analysis of randomized trials. Am Heart J 148: 990-997.
106. Sekiguchi, M., H. Hoshizaki, H. Adachi, S. Ohshima, K. Taniguchi, and M. Kurabayashi. 2004. Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: A randomized comparison of ticlopidine and cilostazol. Circ J 68:610-614.
107. Lee, S.W., S.W. Park, M.K. Hong, et al. 2005. Comparison of cilostazol and clopidogrel after successful coronary stenting. Am J Cardiol 95:859-862.
108. Fattori, R., and T. Piva. 2003. Drug-eluting stents in vascular intervention. Lancet 361:247-249.
109. Take, S., M. Matsutani, H. Ueda, et al. 1997. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 79:1097-1099.
110. Kunishima, T., H. Musha, F. Eto, et al. 1997. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther 19:1058-1066.
111. Sekiya, M., J. Funada, K. Watanabe, M. Miyagawa, and H. Akutsu. 1998. Effects ofprobucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol 82: 144-147.
112. Yamasaki, M., K. Hara, Y. Ikari, et al. 1998. Effects ofcilostazol on late lumen loss after Palmaz-Schatz stent implantation. Cathet Cardiovasc Diagn 44:387-391.
113. Tsuchikane, E., A. Fukuhara, T. Kobayashi, et al. 1999. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 100:21-26.
114. Tsuchikane, E., T. Kobayashi, and N. Awata. 2000. The potential of cilostazol in interventional cardiology. Curr Interv Cardiol Rep 2:143-148.
115. Ochiai, M., K. Eto, S. Takeshita, et al. 1999. Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. Am J Cardiol 84:1074-1076.
116. Tanabe, Y., E. Ito, I. Nakagawa, and K. Suzuki. 2001. Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine. Int J Cardiol 78:285-291.
117. Makutani, S., K. Kichikawa, H. Uchida, et al. 1999. Effect of antithrombotic agents on the patency of PTFE-covered stents in the inferior vena cava: An experimental study. Cardiovasc Interv Radiol 22:232-238.
118. Douglas, J.S., W.S. Weintraub, and D. Holmes. 2003. Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial. Clin Cardiol 26:451-454.
119. Douglas, J.S., Jr., D.R. Holmes, Jr., D.J. Kereiakes, et al. 2005. Coronary stent restenosis in patients treated with cilostazol. Circulation 112:2826-2832.
120. Mitsuhashi, N., Y. Tanaka, S. Kubo, et al. 2004. Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients. Endocr J 51:545-550.
121. Rajagopalan, S., D. Pfenninger, E. Somers, et al. 2003. Effects of cilostazol in patients with Raynaud's syndrome. Am J Cardiol 92:1310-1315.
122. Watanabe, K., S. Ikeda, J. Komatsu, et al. 2003. Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris. Am J Cardiol 92:21-25.